Leap Therapeutics Granted Extension by Nasdaq

The latest update is out from Leap Therapeutics ( (LPTX) ).

On March 12, 2025, Leap Therapeutics received a notification from Nasdaq regarding its failure to maintain the minimum $1.00 per share closing bid price required for continued listing. The company was initially given until September 8, 2025, to comply, and after requesting an extension, it was granted an additional 180 days until March 9, 2026, to meet the requirement. Leap Therapeutics plans to monitor its stock price closely and consider a reverse stock split if necessary to regain compliance. Failure to meet the requirements may result in delisting, although the company may appeal such a decision.

The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.

Spark’s Take on LPTX Stock

According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.

Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.

To see Spark’s full report on LPTX stock, click here.

More about Leap Therapeutics

Leap Therapeutics, Inc. operates within the biopharmaceutical industry, focusing on the development of novel therapeutics for cancer treatment. The company is committed to advancing its pipeline of innovative cancer therapies to address unmet medical needs.

Average Trading Volume: 1,934,755

Technical Sentiment Signal: Sell

Current Market Cap: $11.73M

Learn more about LPTX stock on TipRanks’ Stock Analysis page.